Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $44.22

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year […]

Related Keywords

United States ,Canada ,Robert Young Kim ,Scott Bizily ,Barclays ,Vontobel Holding Ltd ,Jefferies Financial Group ,Royal Bank ,D Molecular Therapeutics Company Profile ,Goldman Sachs Group Inc ,Securities Exchange Commission ,Goldman Sachs Group ,Sectoral Asset Management Inc ,D Molecular Therapeutics Inc ,Nasdaq ,Molecular Therapeutics ,Get Free Report ,Exchange Commission ,Sachs Group ,Sectoral Asset Management ,Molecular Therapeutics Price ,Molecular Therapeutics Company ,Get Free ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Ratings ,Consensus ,